SK C&C has announced a partnership with a domestic pharmaceutical company, Ilsung IS, to amplify efficiency and decrease costs in the pharmaceutical industry through the utilization of generative AI, cloud, and big data technologies. This alliance is set to bring about innovation in the sector by improving workflow efficiency using these advanced digital tools.
The companies have joined forces to expedite and fine-tune the process of reporting adverse drug reactions. SK C&C’s enterprise AI solution, Solur, is instrumental in this initiative, providing a platform for swiftly assembling and submitting detailed adverse event reports required by regulatory authorities.
The collaboration aims to transform the routine of pharmaceutical companies, who are mandated to submit myriad reports on adverse drug events. With the implementation of Solur, the compilation of diverse incidents reported via various means will be streamlined to meet the stringent reporting guidelines set by both domestic and international regulatory bodies.
Solur makes use of the KAERS format for submitting reports in South Korea and the CIOMS format for international reporting. By automating the conversion of incident data into specialized pharmaceutical language, Solur aids healthcare professionals and patients in adhering to the required reporting standards.
Looking ahead, Solur’s application will be extended to other drug surveillance tasks, building a cloud-native system environment integrated with a specialized ‘Drug Safety Database’ for an AI platform focused on drug safety.
As Ilsung IS’s enterprise AI partner, SK C&C pledges support in implementing the AI-based data utilization throughout Ilsung IS’s systems. This includes engaging with large and small-scale language models and harnessing technologies like AI prompts and orchestration to optimize data use within the company, thereby contributing to the company’s maneuverability amid pharmaceutical market changes.
Utilizing generative AI will minimize the risks associated with adverse drug events and promote a safer environment for medication use, all while Ilsung IS benefits from a highly automated workspace facilitated by AI hyperautomation.
Most Important Questions and Answers:
Q: How does the partnership between SK C&C and Ilsung IS leverage AI technology?
A: They are using enterprise AI solution Solur to streamline and automate the reporting of adverse drug reactions, enhancing workflow efficiency in the pharmaceutical industry.
Q: How will the new AI solutions benefit pharmaceutical companies?
A: The solutions will reduce the time and effort required to compile and submit detailed adverse event reports, ensuring compliance with stringent international and domestic regulatory reporting standards.
Q: What formats are supported by Solur for report submissions?
A: Solur supports the KAERS format for South Korea and the CIOMS format internationally.
Key Challenges or Controversies:
The deployment of AI technology in pharmaceuticals brings about certain challenges and controversies:
– Data Privacy and Security: Patient and drug data are sensitive and confidential. Ensuring the protection of this data while utilizing AI is paramount.
– Regulatory Compliance: AI systems must comply with numerous regulations, and keeping up with the ever-changing regulatory landscape can be challenging.
– Model Accuracy and Bias: AI models might suffer from inaccuracy or bias in the data, which can lead to incorrect reporting or analysis.
Advantages:
– Efficiency Improvement: AI can process vast amounts of data quickly, which can significantly improve efficiency in drug safety monitoring.
– Cost Reduction: Automation reduces manual workload and potentially lowers operational costs for pharmaceutical companies.
– Enhanced Drug Safety: AI solutions can detect and report adverse events swiftly, potentially leading to enhanced drug safety for patients.
Disadvantages:
– Technological Integration: Integrating AI solutions into existing systems can be complex and time-consuming.
– Initial Costs: The initial implementation of AI technology can be expensive for some pharmaceutical companies.
– Dependence on Technology: Over-reliance on AI could potentially compromise decision-making in the event of AI system failures or errors.
To find more information about SK C&C and their digital offerings, please visit their official website, using the domain link provided: SK Group.
Similarly, to get more insight into Ilsung IS and their pharmaceutical operations, look for their official domain: Ilsung Pharmaceuticals. Please note that as my assistance is text-based, I can only suggest format structures for links; I cannot verify URLs’ validity or current operational status.
The source of the article is from the blog qhubo.com.ni